Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSS | P25774 | 4/20 | 0.51 |
| ▸ | CTSK | P43235 | 3/20 | 0.51 |
| ▸ | CA2 | P00918 | 2/20 | 0.48 |
| ▸ | PPARA | Q07869 | 2/20 | 0.47 |
| ▸ | CTSL | P07711 | 1/20 | 0.46 |
| ▸ | CTSB | P07858 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.45 |
| ▸ | MEN1 | O00255 | 2/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | CTSD | P07339 | 4/20 | 0.44 |
| ▸ | REN | P00797 | 1/20 | 0.44 |
| ▸ | PPARG | P37231 | 1/20 | 0.43 |
| ▸ | BACE1 | P56817 | 1/20 | 0.43 |
| ▸ | SYK | P43405 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7139596 | 0.92 | CTSK (0.51) | CTSSCTSKCA2PPARACTSL | |
| SCHEMBL7136265 | 0.87 | MEN1 (0.48) | CTSSCTSKCTSLCTSBKMT2A | |
| SCHEMBL7133774 | 0.87 | CTSS (0.63) | CTSSCTSKPPARACTSLCTSB | |
| SCHEMBL7137837 | 0.87 | CTSS (0.61) | CTSSCTSKPPARACTSLCTSB | |
| SCHEMBL7139496 | 0.85 | HPGD (0.48) | CTSSCTSLCTSBKMT2AMEN1 | |
| SCHEMBL7137259 | 0.83 | CTSD (0.57) | CTSSCTSKCTSLCTSBKMT2A | |
| SCHEMBL7136919 | 0.83 | MEN1 (0.44) | CTSSCTSLCTSBKMT2AMEN1 | |
| SCHEMBL7139684 | 0.81 | CTSS (0.49) | CTSSCTSKCA2CTSLCTSB | |
| SCHEMBL7796796 | 0.81 | ACE (0.43) | CTSSCTSLCTSB | |
| SCHEMBL18257555 | 0.81 | CTSD (0.56) | CTSSCTSKCTSLCTSBKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030092634-A1 | Novel compounds and compositions as protease inhibitors | AXYS PHARMACEUTICALS, INC. | 2003-05-15 | — | — | US | disclosed |
| US-6506733-B1 | Which process comprises hydrogenating a compound of Formula 9: presence of a catalytic amount of 20% palladium hydroxide on carbon. | AXYS PHARMACEUTICALS, INC. | 2003-01-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030092634-A1 | Novel compounds and compositions as protease inhibitors | SERPINB1, HPN, CTRL | CTSS 9/4885CTSK 29/4885CA2 674/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.